Skip to content

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders: A Prospective Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04224818
Enrollment
140
Registered
2020-01-13
Start date
2018-07-11
Completion date
2019-08-30
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor Ovarian Reserve

Brief summary

This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in patients with poor ovarian reserve seeking IVF/ICSI treatment.

Detailed description

Women with POR (Bologna criteria) manifest a very low follicular response to controlled ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of oocyte maturation was shown to improve follicle collection yield and oocyte maturation in women with predicted normal ovarian response. These benefits have been attributed to the GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion. The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for final oocyte maturation improve oocyte collection and maturation rate

Interventions

Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)

DRUGhCG (standard)

human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)

Sponsors

American University of Beirut Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Normal uterine cavity (as assessed by hysteroscopy or HSG). * Normal hormonal investigation: TSH, PRL. * Low ovarian reserve patients (AMH\<1.5ng/ml, AFC of 7 or less, 5 oocytes or less retrieved in a previous cycle)

Exclusion criteria

* Abnormal uterine cavity (Hysteroscopy or HSG) * Evidence of untreated endocrine disorders (abnormal TSH, prolactin, testosterone and androstenedione concentrations)

Design outcomes

Primary

MeasureTime frameDescription
Number of oocytes retrieved (oocyte collection rate)38 hrsthe total number of oocytes retrieved divided by the number of follicles aspirated (diameter ≥10 mm) on the day of oocyte retrieval
Number of mature oocytes (oocyte maturation rate)38 hrsthe ratio of MII oocytes to the number of collected oocytes

Secondary

MeasureTime frameDescription
Miscarriage rate12 weeksthe spontaneous loss of a clinical pregnancy occurring before 12 completed weeks of gestational age
Fertilization rate48 hrsthe ratio of normal fertilized oocytes (2PN) to the number of oocytes used for fertilization
Clinical pregnancy rate7 weeksthe presence of fetal cardiac activity confirmed by transvaginal ultrasound 7 weeks after embryo transfer
Implantation rate7 weeksthe number of gestational sacs visualized on ultrasound examination divided by the number of embryos transferred

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026